A turning point after a standoff
The FDA's decision closes a long standoff, during which a senior official described AMT-130 as a “failed product.” The regulator later reversed course and agreed to review the application.
According to uniQure, the FDA granted the therapy a faster review and is considering holding a meeting of outside experts to discuss the application.
Data and controversy
In September, uniQure said AMT-130 failed to significantly slow disease progression in a four-year trial, sending its shares sharply lower.
The application is based on early- to mid-stage study results comparing treated patients with a group from an external Huntington's disease database.

















